CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients

Elisabetta Todisco, Luca Castagna, Barbara Sarina, Rita Mazza, Massimo Magagnoli, Monica Balzarotti, Andrea Nozza, Licia Siracusano, Inna Timofeeva, Antonella Anastasia, Monica Demarco, Armando Santoro

Research output: Contribution to journalArticle

Abstract

Our goal was to optimize use of granulocyte colony-stimulating factor (G-CSF) after high-dose chemotherapy and autologous peripheral blood stem-cell transplantation in lymphoma patients, limiting G-CSF administration to patients infusing a suboptimal CD34+ cell number. Of 124 consecutive patients with histologically proven Hodgkin's and non-Hodgkin's lymphoma from January 2001 to June 2004, 60 patients (group 1) given ≥5 × 106/kg CD34+ cells received no G-CSF; 64 patients (group 2) given ≤5 × 106/kg CD34+ cells received G-CSF from day +5 after stem-cell reinfusion. The median times to reach 0.5 × 10 9/L and 1.0 × 109/L neutrophils were, respectively, 3 and 4 d shorter in G-CSF group and this difference was statistically significant (P = 0.0014; P = 0.0001). In terms of antibiotic and antimycotic requirements, gastrointestinal toxicity, days of hospitalization, and transfusion requirements, no differences were demonstrated between the two groups. No statistically significant difference was demonstrated for the total number of febrile episodes (52 for group 1; 53 for group 2; P = 0.623) and the median number of febrile days (2 d for both groups). Myeloid reconstitution values for both groups agree with published results for autotransplanted patients treated with G-CSF from 7 to 14 d. Also, major clinical events, antibiotic, antimycotic, and transfusion requirements, and hospital stay were similar to published findings. Our data suggest that G-CSF administration can be safely optimized, used only for patients infused with a suboptimal CD34 + cell dose.

Original languageEnglish
Pages (from-to)111-116
Number of pages6
JournalEuropean Journal of Haematology
Volume78
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Granulocyte Colony-Stimulating Factor
Lymphoma
Drug Therapy
Fever
Anti-Bacterial Agents
Peripheral Blood Stem Cell Transplantation
Hodgkin Disease
Non-Hodgkin's Lymphoma
Length of Stay
Hospitalization
Neutrophils
Stem Cells
Cell Count

Keywords

  • Growth factor
  • High-dose chemotherapy
  • Lymphoma
  • Peripheral stem cells

ASJC Scopus subject areas

  • Hematology

Cite this

@article{defa83d968b944fb807de7fa2c31d00b,
title = "CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients",
abstract = "Our goal was to optimize use of granulocyte colony-stimulating factor (G-CSF) after high-dose chemotherapy and autologous peripheral blood stem-cell transplantation in lymphoma patients, limiting G-CSF administration to patients infusing a suboptimal CD34+ cell number. Of 124 consecutive patients with histologically proven Hodgkin's and non-Hodgkin's lymphoma from January 2001 to June 2004, 60 patients (group 1) given ≥5 × 106/kg CD34+ cells received no G-CSF; 64 patients (group 2) given ≤5 × 106/kg CD34+ cells received G-CSF from day +5 after stem-cell reinfusion. The median times to reach 0.5 × 10 9/L and 1.0 × 109/L neutrophils were, respectively, 3 and 4 d shorter in G-CSF group and this difference was statistically significant (P = 0.0014; P = 0.0001). In terms of antibiotic and antimycotic requirements, gastrointestinal toxicity, days of hospitalization, and transfusion requirements, no differences were demonstrated between the two groups. No statistically significant difference was demonstrated for the total number of febrile episodes (52 for group 1; 53 for group 2; P = 0.623) and the median number of febrile days (2 d for both groups). Myeloid reconstitution values for both groups agree with published results for autotransplanted patients treated with G-CSF from 7 to 14 d. Also, major clinical events, antibiotic, antimycotic, and transfusion requirements, and hospital stay were similar to published findings. Our data suggest that G-CSF administration can be safely optimized, used only for patients infused with a suboptimal CD34 + cell dose.",
keywords = "Growth factor, High-dose chemotherapy, Lymphoma, Peripheral stem cells",
author = "Elisabetta Todisco and Luca Castagna and Barbara Sarina and Rita Mazza and Massimo Magagnoli and Monica Balzarotti and Andrea Nozza and Licia Siracusano and Inna Timofeeva and Antonella Anastasia and Monica Demarco and Armando Santoro",
year = "2007",
month = "2",
doi = "10.1111/j.1600-0609.2006.00793.x",
language = "English",
volume = "78",
pages = "111--116",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients

AU - Todisco, Elisabetta

AU - Castagna, Luca

AU - Sarina, Barbara

AU - Mazza, Rita

AU - Magagnoli, Massimo

AU - Balzarotti, Monica

AU - Nozza, Andrea

AU - Siracusano, Licia

AU - Timofeeva, Inna

AU - Anastasia, Antonella

AU - Demarco, Monica

AU - Santoro, Armando

PY - 2007/2

Y1 - 2007/2

N2 - Our goal was to optimize use of granulocyte colony-stimulating factor (G-CSF) after high-dose chemotherapy and autologous peripheral blood stem-cell transplantation in lymphoma patients, limiting G-CSF administration to patients infusing a suboptimal CD34+ cell number. Of 124 consecutive patients with histologically proven Hodgkin's and non-Hodgkin's lymphoma from January 2001 to June 2004, 60 patients (group 1) given ≥5 × 106/kg CD34+ cells received no G-CSF; 64 patients (group 2) given ≤5 × 106/kg CD34+ cells received G-CSF from day +5 after stem-cell reinfusion. The median times to reach 0.5 × 10 9/L and 1.0 × 109/L neutrophils were, respectively, 3 and 4 d shorter in G-CSF group and this difference was statistically significant (P = 0.0014; P = 0.0001). In terms of antibiotic and antimycotic requirements, gastrointestinal toxicity, days of hospitalization, and transfusion requirements, no differences were demonstrated between the two groups. No statistically significant difference was demonstrated for the total number of febrile episodes (52 for group 1; 53 for group 2; P = 0.623) and the median number of febrile days (2 d for both groups). Myeloid reconstitution values for both groups agree with published results for autotransplanted patients treated with G-CSF from 7 to 14 d. Also, major clinical events, antibiotic, antimycotic, and transfusion requirements, and hospital stay were similar to published findings. Our data suggest that G-CSF administration can be safely optimized, used only for patients infused with a suboptimal CD34 + cell dose.

AB - Our goal was to optimize use of granulocyte colony-stimulating factor (G-CSF) after high-dose chemotherapy and autologous peripheral blood stem-cell transplantation in lymphoma patients, limiting G-CSF administration to patients infusing a suboptimal CD34+ cell number. Of 124 consecutive patients with histologically proven Hodgkin's and non-Hodgkin's lymphoma from January 2001 to June 2004, 60 patients (group 1) given ≥5 × 106/kg CD34+ cells received no G-CSF; 64 patients (group 2) given ≤5 × 106/kg CD34+ cells received G-CSF from day +5 after stem-cell reinfusion. The median times to reach 0.5 × 10 9/L and 1.0 × 109/L neutrophils were, respectively, 3 and 4 d shorter in G-CSF group and this difference was statistically significant (P = 0.0014; P = 0.0001). In terms of antibiotic and antimycotic requirements, gastrointestinal toxicity, days of hospitalization, and transfusion requirements, no differences were demonstrated between the two groups. No statistically significant difference was demonstrated for the total number of febrile episodes (52 for group 1; 53 for group 2; P = 0.623) and the median number of febrile days (2 d for both groups). Myeloid reconstitution values for both groups agree with published results for autotransplanted patients treated with G-CSF from 7 to 14 d. Also, major clinical events, antibiotic, antimycotic, and transfusion requirements, and hospital stay were similar to published findings. Our data suggest that G-CSF administration can be safely optimized, used only for patients infused with a suboptimal CD34 + cell dose.

KW - Growth factor

KW - High-dose chemotherapy

KW - Lymphoma

KW - Peripheral stem cells

UR - http://www.scopus.com/inward/record.url?scp=33846059463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846059463&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2006.00793.x

DO - 10.1111/j.1600-0609.2006.00793.x

M3 - Article

C2 - 17313558

AN - SCOPUS:33846059463

VL - 78

SP - 111

EP - 116

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 2

ER -